Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $88.00

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been given a consensus rating of “Buy” by the twelve analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $92.44.

Several research firms recently commented on JANX. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Stifel Nicolaus raised their target price on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. Finally, Scotiabank lowered their price target on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 28th.

Insider Activity

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the transaction, the insider now owns 82,139 shares in the company, valued at $3,473,658.31. This trade represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David Alan Campbell sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $60.00, for a total value of $300,000.00. Following the completion of the transaction, the chief executive officer now owns 293,054 shares in the company, valued at approximately $17,583,240. This trade represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,002 shares of company stock worth $2,684,703 over the last quarter. 29.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Janux Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Plato Investment Management Ltd lifted its position in Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after buying an additional 187 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after buying an additional 442 shares in the last quarter. Rhumbline Advisers lifted its position in Janux Therapeutics by 1.6% during the fourth quarter. Rhumbline Advisers now owns 38,153 shares of the company’s stock worth $2,043,000 after buying an additional 599 shares in the last quarter. Kennedy Capital Management LLC lifted its position in Janux Therapeutics by 7.9% during the fourth quarter. Kennedy Capital Management LLC now owns 12,713 shares of the company’s stock worth $681,000 after buying an additional 928 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its position in Janux Therapeutics by 5.8% during the fourth quarter. MetLife Investment Management LLC now owns 17,298 shares of the company’s stock worth $926,000 after buying an additional 949 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $31.81 on Thursday. The firm has a market capitalization of $1.88 billion, a PE ratio of -27.19 and a beta of 3.23. Janux Therapeutics has a fifty-two week low of $28.92 and a fifty-two week high of $71.71. The stock’s 50-day simple moving average is $39.91 and its 200-day simple moving average is $47.17.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Sell-side analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.